Crizotinib — supply status, manufacturers & alternatives

Crizotinib

—

🇦🇺 AUST R 190965 · Pfizer Australia Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia

In supply in Australia

No active shortage reported.

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Crizotinib
Therapeutic category	Auto-created by INVIMA — Desabastecimiento de medicamentos (Colombia) scraper
Controlled substance	No
Marketing-authorisation holders	Pfizer Australia Pty Ltd

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

4 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk

Msn Laboratories Private LTDNavinta LLCChongqing Huapont Shengchem Pharmaceutical CO LTDHetero Labs LTD

Manufacturing countries: India, United States, China · Source: FDA List of Drug Master Files

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
XALKORI crizotinib	250 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
XALKORI crizotinib	200 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.